Applying the same criteria to patients with 1 or more GLP-1 RA or LD-L prescription claim in MarketScan yielded 58,311 patients using a GLP-1 RA other than liraglutide and 84,671 using LD-L.

An analysis of real-world data from a single medical center is providing insight into the effects of off-label glucagon-like peptide 1 (GLP-1) receptor agonist (RA) and sodium-glucose ...

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose ...

Researchers analyzed data from the US Collaborative Network of TriNetX of 140,308 patients with T2D who were initiated on tirzepatide or a GLP-1 RA between June 1, 2022, and June 30, 2023.

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an incr ...

TUESDAY, Nov. 12, 2024 (HealthDay News) -- For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are ...

The researchers observed an increase in the number of adolescents and young adults with GLP-1 RA dispensing, from 8722 to 60,567 (594.4%), between 2020 and 2023.

GLP-1 RA users also lost a few pounds after 6 months of treatment (204.17 lb from 206.04 lb at baseline), while those not on these agents gained a significant amount of weight (180.96 lb at ...

In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite. (HealthDay News) — For patients with ischemic stroke, sodium-glucose ...